London South East

Relvar Ellipta approved in Japan for COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta® (fluticasone furoate ...
The Business Journals

GSK snags $15 million from Theravance after European approval of asthma, COPD drug

Theravance Inc. will pay GlaxoSmithKline $15 million for winning European approval of the lung disease treatment Relvar Ellipta and will pay out another $15 million when GSK launches the drug ...
Pharmabiz

Relvar Ellipta receives Japanese approval to treat patients with COPD

GlaxoSmithKline plc (GSK) and Innoviva, Inc. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar Ellipta (fluticasone furoate/vilanterol 100/25 mcg) for the ...
News Medical

Nonadherence to COPD medication increases hospital admissions and mortality

Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...
Healthline

What’s the Difference Between Short-Acting and Long-Acting Bronchodilators? Answered by an Expert

Short-acting bronchodilators offer quick relief of respiratory symptoms, with effects lasting from 30 minutes to several hours. They are often used as a rescue medication. Long-acting bronchodilators ...
Healthline

How Do I Prevent Lung Infections with COPD? Expert Answers

When living with chronic obstructive pulmonary disease (COPD), you can help prevent lung infections by quitting smoking and avoiding irritants such as secondhand smoke and strong scents. It’s ...